Profitelligence Profitelligence · Filing Ledger Open DHR research →

Form 8-K · Current Report · Filed 2025-07-31

Brian W. Ellis to Step Down as General Counsel at Danaher

On July 28, 2025, Brian W. Ellis, Senior Vice President and General Counsel of Danaher Corporation, announced his intention to relinquish his role as General Counsel effective August 25, 2025. He will transition to a Senior Vice President role until his retirement on February 28, 2026.

Filer
Danaher Corporation DHR · NYSE
Filed
Accession
0000313616-25-000172
CIK
0000313616
Signal
High impactHealthcare

Items reported

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

CFO Resignation
Item 9.01

Financial Statements and Exhibits

No viable tag

Market reaction

Close before filing

$203.99

Next session

-3.4%

Since filing

-4.4%

Latest close

$194.98

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from DHR reporting the same item, with the next session's move:

About Danaher Corporation

Danaher Corporation is a globally recognized science and technology company specializing in the development, design, and manufacturing of diverse industrial and healthcare products. With a primary focus on innovations in diagnostics, life sciences, dental, and environmental and applied solutions, Danaher serves a multitude of industries and market sectors. Its cutting-edge diagnostic equipment aids medical professionals in delivering precise healthcare, while its life sciences tools and technologies propel biomedical research and development. The company's environmental solutions also play a key role in enhancing water quality analysis and management. Headquartered in Washington, D.C., Danaher is renowned for its strong operational culture exemplified by the Danaher Business System (DBS), which emphasizes continuous improvement and sustainable innovation. This approach has solidified Danaher's presence and influence in both developing specialized solutions and improving efficiency across global markets. The company's strategic acquisitions and consistent focus on innovation have positioned it as a leader in delivering essential solutions that drive significant improvements for healthcare, research, and industrial clients.

Exchange NYSE Industry Diagnostics & Research Company website ↗

Never miss another DHR filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts